knowledge -WSS

knowledge

author：comprehensive 2025-08-26 07:42:26 - browse：48

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Independent physicians launch a new lobbying group

hotspot

WSS

New brain studies show LSD's effects on the brain in full color

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

ER docs worry over extreme heat as a 'mass casualty event'

What the cancer research community can learn from the Covid response

NIH director takes cautious approach to Biden drug pricing priority

The surgeon had a dilemma only a Nazi medical text could resolve

leisure time

knowledge

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The tragedy of Johnson & Johnson’s Covid vaccine

Alkermes shareholders re

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Parkinson’s finding may lead to tests and, someday, treatments

What does generative AI mean for health care? We asked experts

AI generated plenty of interest at JPM but not a lot of trust

DIEP, the 'gold standard' of breast reconstruction, is under threat

How digital therapeutics firms are pivoting after Pear's bankruptcy

focus

Dramatically reducing cancer deaths requires the PASTEUR Act

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Attacks on the drug industry will lead to fewer breakthroughs

Microsoft strikes partnership with Duke Health to advance health AI

Microsoft strikes partnership with Duke Health to advance health AI

eGenesis tests gene

focus

hotspot

entertainment

Wikipedia